Condition: Epilepsy · Sponsor: UCB Biopharma SRL
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
This description comes directly from the study's public registry record.
UCB Cares · 0018445992273 · UCBCares@ucb.com
Always discuss trial participation with your own doctor first.
| Ep0156 259 | Hawthorne, New York, United States | Completed |
| Ep0156 237 | Durham, North Carolina, United States | Completed |
| Ep0156 204 | Leuven, Belgium | Withdrawn |
| Ep0156 240 | Prague, Czechia | Withdrawn |
| Ep0156 207 | Loos, France | Withdrawn |
| Ep0156 209 | Freiburg im Breisgau, Germany | Withdrawn |
| Ep0156 210 | Budapest, Hungary | Completed |
| Ep0156 247 | Budapest, Hungary | Completed |
| Ep0156 232 | Miskolc, Hungary | Completed |
| Ep0156 230 | Roma, Italy | Completed |
| Ep0156 803 | Bunkyō City, Japan | Active Not Recruiting |
| Ep0156 808 | Chūō, Japan | Active Not Recruiting |
+ 24 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04715646